[Cost-Effectiveness Analysis of Maribavir in Patients with Post-Transplant Cytomegalovirus Infection or Disease that are Refractory or Resistant to Conventional Therapy]. (2023). Farmeconomia. Health Economics and Therapeutic Pathways, 24(1). https://doi.org/10.7175/fe.v24i1.1548